HC Wainwright Has Bearish Forecast for MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Investment analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a research note issued on Wednesday, May 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.43 per share for the year, down from their prior forecast of $0.45. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2030 earnings at $1.78 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million.

MIST has been the topic of a number of other research reports. Wells Fargo & Company dropped their price target on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Thursday. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday. Zacks Research cut Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Raymond James Financial assumed coverage on Milestone Pharmaceuticals in a research report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ MIST opened at $1.51 on Monday. Milestone Pharmaceuticals has a one year low of $1.00 and a one year high of $3.06. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09. The business’s fifty day moving average price is $1.70 and its 200-day moving average price is $1.93. The stock has a market capitalization of $187.37 million, a PE ratio of -2.21 and a beta of 1.04.

Insider Transactions at Milestone Pharmaceuticals

In related news, CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $2.26, for a total transaction of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.50% of the company’s stock.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning lifted its holdings in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after purchasing an additional 10,000 shares in the last quarter. Bay Rivers Group lifted its holdings in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares in the last quarter. Strategic Family Wealth Counselors L.L.C. purchased a new stake in Milestone Pharmaceuticals during the 4th quarter worth about $25,000. Finally, Eaton Financial Holdings Company LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.